EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

New‐Onset Headache After SARS ‐ CoV ‐2 Infection and Vaccination: Results From Three Population‐Based Cohorts in Norway

Kristine Blix, Ida Laake, Ida Henriette Caspersen iD, Berit Feiring, Anna Hayman Robertson, Siri N Skodvin iD, Siri Mjaaland, Per Magnus, Anker Stubberud, Marte-Helene Bjørk iD, Lill Trogstad

European Journal of Neurology · 2025

DOI: 10.1111/ene.70437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Kristine Blix und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: COVID-19, Headache, COVID-19 Vaccines, Vaccination. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Norwegian Institute of Public Health, Norges Forskningsråd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Persistent headache after SARS‐CoV‐2 infections and vaccination has been reported. However, limited data exist on the risk of new‐onset headache after these exposures compared to unexposed periods in the general population.

Methods

We used data from three population‐based cohorts ( N = 85,774, age 19–81 years). SARS‐CoV‐2 infections and vaccinations were obtained from national registries and questionnaires. Before and after Omicron emergence, participants stated whether they had been suffering from headache during the past year, reported headache characteristics, and time of onset. Time‐dependent exposures were used to investigate the impact of SARS‐CoV‐2 infection and vaccination on the risk of new‐onset headache. Headache subtypes were secondary outcomes.

Results

SARS‐CoV‐2 infection and first and second vaccine doses were associated with increased risk of new‐onset headache. The three cohorts, representing different age groups, were analyzed separately. For pre‐Omicron infections, the hazard ratio (HR) was 6.7 (95% confidence interval (CI) 4.8–9.2) and 6.5 (95% CI 3.8–11.1) among middle‐aged women and men, respectively. For Omicron infection, HRs were 4.7 (95% CI 4.1–5.4) and 4.5 (95% CI 3.7–5.4), respectively. The risk increased with infection severity. Corresponding HRs for first and second vaccine doses, administered during low transmission, were 1.6 and 1.7, respectively, in women, and 1.5 for both doses in men. The third dose, given before the Omicron surge, was associated with 20%–40% protection against new‐onset headache.

Conclusions

SARS‐CoV‐2 infection was strongly associated with new‐onset headache. Primary vaccination was associated with a small increased risk of headache during a low‐transmission period, whereas booster vaccination offered protection during high‐transmission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HeadacheCOVID-19 VaccinesVaccinationHumansMaleFemaleMiddle AgedAgedAdultNorwayAged, 80 and overYoung AdultCohort StudiesRegistriesSARS-CoV-2

Stichwörter der Autor:innen

SARS‐CoV‐2general populationheadacheinfectionvaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway.
  • Center for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
  • NorHead, Norwegian Headache Research Centre, Norwegian University of Science and Technology, Trondheim, Norway.

ORCID-Profile: Ida Henriette Caspersen, Siri N Skodvin, Marte-Helene Bjørk

Förderung

  • Norwegian Institute of Public Health
  • Norges Forskningsråd

Zitieren

APA

Blix, K., Laake, I., Caspersen, I. H., Feiring, B., Robertson, A. H., Skodvin, S. N., Mjaaland, S., Magnus, P., Stubberud, A., Bjørk, M. H., & Trogstad, L. (2025). New‐Onset Headache After SARS ‐ CoV ‐2 Infection and Vaccination: Results From Three Population‐Based Cohorts in Norway. European Journal of Neurology. https://doi.org/10.1111/ene.70437

Vancouver

Blix K, Laake I, Caspersen IH, Feiring B, Robertson AH, Skodvin SN, et al. New‐Onset Headache After SARS ‐ CoV ‐2 Infection and Vaccination: Results From Three Population‐Based Cohorts in Norway. European Journal of Neurology. 2025. doi:10.1111/ene.70437

BibTeX
@article{Blix2025,
  author = {Blix, Kristine and Laake, Ida and Caspersen, Ida Henriette and Feiring, Berit and Robertson, Anna Hayman and Skodvin, Siri N and Mjaaland, Siri and Magnus, Per and Stubberud, Anker and Bjørk, Marte-Helene and Trogstad, Lill},
  title = {New‐Onset Headache After SARS ‐ CoV ‐2 Infection and Vaccination: Results From Three Population‐Based Cohorts in Norway},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70437}
}
Kostenlos starten →